WO2004037159A3 - Composes, compositions et methodes permettant de moduler le metabolisme des graisses - Google Patents

Composes, compositions et methodes permettant de moduler le metabolisme des graisses Download PDF

Info

Publication number
WO2004037159A3
WO2004037159A3 PCT/IL2003/000860 IL0300860W WO2004037159A3 WO 2004037159 A3 WO2004037159 A3 WO 2004037159A3 IL 0300860 W IL0300860 W IL 0300860W WO 2004037159 A3 WO2004037159 A3 WO 2004037159A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
compounds
fat metabolism
modulating fat
Prior art date
Application number
PCT/IL2003/000860
Other languages
English (en)
Other versions
WO2004037159A2 (fr
Inventor
Georges Gaudriault
Ahmet Kilinc
Olivier Bousquet
Anne Goupil-Lamy
Itzik Harosh
Original Assignee
Obetherapy Biotechnology
Georges Gaudriault
Ahmet Kilinc
Olivier Bousquet
Anne Goupil-Lamy
Itzik Harosh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obetherapy Biotechnology, Georges Gaudriault, Ahmet Kilinc, Olivier Bousquet, Anne Goupil-Lamy, Itzik Harosh filed Critical Obetherapy Biotechnology
Priority to AU2003274652A priority Critical patent/AU2003274652A1/en
Publication of WO2004037159A2 publication Critical patent/WO2004037159A2/fr
Publication of WO2004037159A3 publication Critical patent/WO2004037159A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes, des compositions ainsi que des méthodes d'identification de composés candidats, permettant de moduler le métabolisme des graisses et/ou d'inhiber l'activité de Apobec-1.
PCT/IL2003/000860 2002-10-23 2003-10-23 Composes, compositions et methodes permettant de moduler le metabolisme des graisses WO2004037159A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274652A AU2003274652A1 (en) 2002-10-23 2003-10-23 Compounds, compositions and methods for modulating fat metabolism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42031602P 2002-10-23 2002-10-23
US60/420,316 2002-10-23

Publications (2)

Publication Number Publication Date
WO2004037159A2 WO2004037159A2 (fr) 2004-05-06
WO2004037159A3 true WO2004037159A3 (fr) 2004-07-15

Family

ID=32176552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000860 WO2004037159A2 (fr) 2002-10-23 2003-10-23 Composes, compositions et methodes permettant de moduler le metabolisme des graisses

Country Status (2)

Country Link
AU (1) AU2003274652A1 (fr)
WO (1) WO2004037159A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881137B1 (ko) 2007-08-07 2009-02-02 충남대학교산학협력단 신규 돼지 페로몬 성 화합물과 그 제조방법 및 발정 유도용조성물
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548283A1 (fr) * 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Heterocycles mutagenes
EP1598354A1 (fr) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Composes contenant un groupement n-heteroaryle lie a un cycle condense et leur utilisation comme inhibiteurs du nad(p)h oxidases et de l'activation plaquettaire
ITMI20041567A1 (it) * 2004-07-30 2004-10-30 Maycos Italiana Di Comini Miro "derivati n-acilati di acidi bicarbossilici con amminoacidi e con idrolizzati proteici vegetali e loro applicazione in prodotti cosmetici, dermofarmaceutici e farmaceutici"
EP1746099A1 (fr) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Inhibiteurs de Mnk1 ou Mnk2
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2608405A1 (fr) * 2005-05-17 2006-11-23 Schering Corporation Heterocycles utilises comme agonistes du recepteur de l'acide nicotinique dans le traitement de la dyslipidemie
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
EP1980237B1 (fr) * 2006-01-06 2013-10-02 Ajinomoto Co., Inc. Agent gelifiant
JP2009525961A (ja) 2006-01-20 2009-07-16 シェーリング コーポレイション 異常脂質血症の処置のためのニコチン酸受容体アゴニストとしての複素環
EP2004656B1 (fr) 2006-04-07 2013-07-10 Boehringer Ingelheim International GmbH Thiénopyrimidines ayant une activité inhibitrice mnk1/mnk2 utilisées dans des compositions pharmaceutiques
WO2007139497A1 (fr) * 2006-05-30 2007-12-06 Aprea Ab Dérivés levoglucosenone pour le traitement de troubles tels que cancer, maladies auto-immunes et maladies du cœur.
EP1889847A1 (fr) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Dérivés de pyrrolopyrimidine pour applications pharmaceutiques
US20080009508A1 (en) * 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
EP2164500B1 (fr) * 2007-05-25 2013-12-04 Idogen AB Utilisation de zéburaline pour le traitement de maladies autoimmunitaires ou pour un rejet immunitaire de greffes
CN103983627A (zh) 2008-06-17 2014-08-13 韩国巴斯德研究所 作为抗结核病药的吡啶并嘧啶化合物
NZ591113A (en) 2008-08-26 2012-07-27 Boehringer Ingelheim Int Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions
KR100883548B1 (ko) * 2008-10-15 2009-02-13 충남대학교산학협력단 돼지 페로몬성 우레아계 화합물과 그 제조방법 및 이를 함유하는 발정 유도용 조성물
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
FR2940611B1 (fr) 2008-12-30 2012-01-13 Oreal Association de monosaccharides et d'adenosine et son utilisation en cosmetique
BR112012002807B1 (pt) * 2009-08-07 2018-07-10 Adama Makhteshim Ltd. Derivados de 5-flúor-2-oxopirimidina-1(2h)- caboxilato, composição e processo para controle e prevenção de ataque fúngico em uma planta de ataque fúngico em uma planta
UA112284C2 (uk) * 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні 5-фторпіримідинону
EP2480082A4 (fr) 2009-09-25 2014-01-15 Merck Sharp & Dohme Aminopipéridines substituées utilisées en tant qu'inhibiteurs de la dipeptidyl peptidase-iv dans le cadre du traitement du diabète
FR2951639B1 (fr) 2009-10-22 2011-11-04 Oreal Utilisation de l'adenosine et/ou de l'un de ses derives comme agent de traitement de la transpiration humaine
WO2011085000A2 (fr) * 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Dérivés d'acides gras et analogues de médicaments
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
KR20130008538A (ko) 2010-02-26 2013-01-22 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물을 위한 ｍｎｋ１／ｍｎｋ２ 억제 활성을 갖는 ４－［사이클로알킬옥시 （헤테로） 아릴아미노］ 티에노 ［２，３－ｄ］ 피리미딘
EP2539343B1 (fr) 2010-02-26 2015-12-30 Evotec International GmbH Thiénopyrimidines contenant un groupe alkyle substitué pour des compositions pharmaceutiques
US20130324461A1 (en) * 2010-08-26 2013-12-05 Michail V. Sitkovsky Methods and compositions for preventing or treating obesity
SG11201402826YA (en) 2011-12-22 2014-12-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2013137832A1 (fr) * 2012-03-16 2013-09-19 Nanyang Technological University Inhibiteurs de myostatine
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR20150090894A (ko) 2012-10-29 2015-08-06 코크리스탈 파마, 아이엔씨. 바이러스 감염 및 암 치료용 피리미딘 뉴클레오티드 및 그들의 모노포스페이트 프로드럭
SG11201504554UA (en) 2012-12-21 2015-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
UA115462C2 (uk) 2012-12-28 2017-11-10 Адама Махтешім Лтд. Похідні n-(заміщеного)-5-фтор-4-іміно-3-метил-2-оксо-3,4-дигідропіримідин-1(2h)-карбоксилату
UA117743C2 (uk) 2012-12-28 2018-09-25 Адама Махтешім Лтд. N-(заміщені)-5-фтор-4-іміно-3-метил-2-оксо-3,4-дигідропіримідин-1(2h)-карбоксамідні похідні
MX2015008565A (es) 2012-12-31 2015-09-07 Dow Agrosciences Llc Derivados de 3-alquil-5-fluoro-4-sustituido-imino-3,4-dihidropirim idin-2(1h)-ona como fungicidas.
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
WO2016178113A1 (fr) 2015-05-05 2016-11-10 Pfizer Inc. 2-thiopyrimidinones
CN109503587B (zh) * 2017-09-14 2022-01-11 辽宁利锋科技开发有限公司 双杂环三氮唑核苷类似物的抗肿瘤作用与应用
JP7429799B2 (ja) 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
EP4323362A1 (fr) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Procédés de préparation de carbanucléosides à l'aide d'amides
CN115501234B (zh) * 2021-08-02 2023-08-08 中山大学·深圳 化合物在制备防治脱髓鞘疾病药物的用途
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023044104A1 (fr) * 2021-09-17 2023-03-23 Emory University Phosphoramidates pour le traitement du virus de l'hépatite b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOVOTNY L. ET AL: "Polarographic properties and potential carcinogenicity of some natural nucleosides and their synthetic analogues", BIOELECTROCHEMISTRY AND BIOENERGETICS, vol. 48, 1999, pages 129 - 134, XP002979005 *
SAMILJENKO S.P. ET AL: "Structural peculiarities of 6-azacytosine and its derivatives imply intramolecular H-bonds", J. OF MOLECULAR STRUCTURE, vol. 484, 1999, pages 31 - 38, XP002979006 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186369B2 (en) 2003-07-25 2015-11-17 Idenix Pharmaceuticals, Llc Purine nucleoside analogues for treating flaviviridae including hepatitis C
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
KR100881137B1 (ko) 2007-08-07 2009-02-02 충남대학교산학협력단 신규 돼지 페로몬 성 화합물과 그 제조방법 및 발정 유도용조성물
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US8841314B2 (en) 2011-11-11 2014-09-23 Pfizer Inc. 2-Thiopyrimidinones
US9399626B2 (en) 2011-11-11 2016-07-26 Pfizer Inc. 2-thiopyrimidinones
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones

Also Published As

Publication number Publication date
AU2003274652A8 (en) 2004-05-13
WO2004037159A2 (fr) 2004-05-06
AU2003274652A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
WO2004037159A3 (fr) Composes, compositions et methodes permettant de moduler le metabolisme des graisses
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005082341A3 (fr) Agents non peptidyl a activite de type phsp20 et utilisations correspondantes
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
WO2004020458A3 (fr) Tests et compositions d'identification d'agents modulant l'activite d'agents de desubiquitination
WO2006078287A3 (fr) Inhibiteurs de pde4b
WO2003093441A3 (fr) Procede de regulation de l'expression genique
WO2004047760A3 (fr) Nouveaux composes chimiques
WO2004101763A9 (fr) Enzyme lipolytique lip1
WO2003066802A3 (fr) Analyse d'expression genique au moyen d'agents de croisement
WO2005030129A3 (fr) Inhibiteurs des canaux potassiques a la quinoleine
WO2001014584A3 (fr) Identification d'agents antiviraux
MXPA05006368A (es) Inhibidores aminocianopiridina de proteina cinasa-2 activada por proteina cinasa activada por mitogeno.
WO2005089505A3 (fr) Detection, isolement et utilisations de la renalase (monoamine oxydase de type c)
WO2004033666A3 (fr) Procedes et composes pour inhiber l'activite de hec1 dans le traitement des maladies proliferatives
EP1667685A4 (fr) Inhibiteurs du canal potassique a base de quinazoline
WO2005030792A3 (fr) Inhibiteurs du canal potassique de quinoline
AU2003297700A1 (en) METHODS FOR MODULATING IKKAlpha ACTIVITY
WO2003087054A3 (fr) Methodes d'identification de composes modulant l'activite enzymatique
WO2004063339A3 (fr) Essai de liaison de g-quadruplex et composes utilises a cette fin
AU2003241375A1 (en) Method for identifying modulators of sulfotransferase activity
WO2005056043A3 (fr) Utilisation d'inhibiteurs enzymatiques de h-prune pour la prevention et le traitement des metastases de tumeurs sur-exprimant h-prune
WO2004060878A3 (fr) Inhibiteurs de phosphatases
AU2003285775A1 (en) Method for identifying, analyzing and/or cloning nucleic acid isoforms
WO2002093127A3 (fr) Methodes et reactifs servant a identifier des modulateurs de la reponse a l'insuline et utilisation therapeutique de ces methodes et reactifs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP